Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.
Karen A. A. Gelmon
Consultant or Advisory Role - Amgen; AstraZeneca; GlaxoSmithKline; Novartis; Pfizer; Roche
Frances Boyle
No relevant relationships to disclose
Bella Kaufman
No relevant relationships to disclose
David Huntsman
No relevant relationships to disclose
Alexey Manikhas
No relevant relationships to disclose
Angelo Di Leo
No relevant relationships to disclose
Miguel Martin
No relevant relationships to disclose
Lee Steven Steven Schwartzberg
No relevant relationships to disclose
Susan Faye Faye Dent
No relevant relationships to disclose
Susan Ellard
No relevant relationships to disclose
Katia Sonia Sonia Tonkin
No relevant relationships to disclose
Yasir M. M. Nagarwala
No relevant relationships to disclose
Kathleen I. I. Pritchard
No relevant relationships to disclose
Timothy Joseph Joseph Whelan
No relevant relationships to disclose
Dora Nomikos
No relevant relationships to disclose
Judy-Anne W. W. Chapman
No relevant relationships to disclose
Wendy Parulekar
No relevant relationships to disclose